It is well recognized that sodium/glucose cotransporter 2 inhibitors (SGLT2i) are associated with weight loss in people with type 2 diabetes. However, the time-dependent associations of weight loss with the anthropometric and body fluid measurements and serum parameters during SGLT2i intervention remain unclear. Thus, we aimed to clarify weight loss-related factors, carefully focusing on the clinical process during the long-term intervention with a SGLT2i, tofogliflozin in people with type 2 diabetes. We analyzed data from 775 people with type 2 diabetes that participated in tofogliflozin phase 3 trials. Participants received tofogliflozin (20, or 40 mg; n = 235, and 540, respectively) orally once daily for 52 weeks. The correlation analysis was performed at week 4, 24 and 52. Baseline characteristics showed men (66 %), age (mean: 58 years), HbA1c (8.0 %), BMI (26 kg/m2) and eGFR (84 mL/min/1.73m2). Tofogliflozin significantly reduced body weight at week 4, 24 and 52 (mean: -1.4, -3.0 and -3.0 kg, respectively). At week 4, weight loss was negatively correlated with both the change in body fluid measures (hematocrit, RBC count, serum creatinine level, and uric acid level) and beta-hydroxybutyrate (BHB). At week 24, weight loss was positively correlated with anthropometric measurements (waist and hip circumferences) and hepatic enzymes levels, and negatively correlated with adiponectin, HDL-C, and BHB levels, but not with body fluid measures. Although the values at week 52 were in concert with the results at week 24, there was a modest but significant correlation between weight loss and BHB level. Our results clarified that tofogliflozin reduces weight, especially that of visceral fat in people with type 2 diabetes, at least due to fluid loss initially and to lipolysis in late. Weight loss might contribute to decrease in the hepatic enzymes, whereas it also accompanies an increase in beta-hydroxybutyrate, the safety issue of which to be investigated in future.


A. Yoshida: Employee; Self; Kowa Pharmaceutical Co. Ltd. H. Kusakabe: Employee; Self; Kowa Pharmaceutical Co.Ltd. T. Takamura: None. K. Kaku: Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Mitsubishi Tanabe Pharma Corporation, MSD K.K.. Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Ono Pharmaceutical Co., Ltd.. Advisory Panel; Self; Sanwa Kagaku Kenkyusho Co., Ltd.. Speaker's Bureau; Self; Taisho Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceuticals, Japan Inc., Kowa Pharmaceuticals, Japan Inc.. Advisory Panel; Self; Astellas, Japan Inc. H. Suganami: Employee; Self; Kowa Company, Ltd..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at